Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis.

Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis.

Item
http://www.wikidata.org/entity/Q55058300
Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted TherapiesThalidomide combined with transcatheter artierial chemoembolzation for primary hepatocellular carcinoma: a systematic review and meta-analysis.Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up.The Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma.Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma.Safety of proteasome inhibitors for treatment of multiple myeloma.The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents.Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma.Autologous stem cell transplantation in EBV-positive post-renal transplant refractory multiple myeloma: A case report and literature review.Low expression of neural cell adhesion molecule, CD56, is associated with low efficacy of bortezomib plus dexamethasone therapy in multiple myeloma.Short overview on the current standard of treatment in newly diagnosed multiple myeloma.Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma
P2860

Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis.

Item
http://www.wikidata.org/entity/Q55058300
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Bortezomib-cyclophosphamide-de ...... iple myeloma: a meta-analysis.
@en
Bortezomib-cyclophosphamide-dexamethasone
@nl
type
label
Bortezomib-cyclophosphamide-de ...... iple myeloma: a meta-analysis.
@en
Bortezomib-cyclophosphamide-dexamethasone
@nl
prefLabel
Bortezomib-cyclophosphamide-de ...... iple myeloma: a meta-analysis.
@en
Bortezomib-cyclophosphamide-dexamethasone
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P698
P921
P356
P1433
P1476
Bortezomib-cyclophosphamide-de ...... iple myeloma: a meta-analysis.
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P698
P921